Pfizer (PFE) announced results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor Tukysa as part of an investigational ...

The insulin receptor (IR) is a prototypical receptor tyrosine kinase that orchestrates critical cellular processes, including metabolism, cell growth and differentiation. Activation of the IR involves ...

In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...

Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...

MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract ...

US biotech Amgen (Nasdaq: AMGN) has won approval from the US regulator for Uplizna (inebilizumab-cdon) to treat adults with ...

Soluble TAM receptors (sTAMs) could serve as biomarkers for RA, indicating disease activity, severity, and prognosis, though standardized detection methods are needed. TAM receptors could emerge as ...